Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction
Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction
复制标题
DOI：
10.1016/j.jcmg.2015.11.024
复制
发表时间：
2016-10-01
影响因子：
14
通讯作者：
Ky, Bonnie
中科院分区：
文献类型：
--
作者：
Narayan, Hari K.;French, Benjamin;Ky, Bonnie
本研究试图确定超声心动图衍生的心肌力学测量与癌症治疗相关的心功能障碍（CTRCD）之间的关系。有一个关键的需要在增加的风险toxicity.METHODS的早期检测患者进行了前瞻性，纵向队列研究的乳腺癌参与者接受阿霉素和/或曲妥珠单抗治疗。在治疗开始前（基线）和治疗期间及治疗完成后的标准化随访时间间隔进行超声心动图检查。对射血分数（EF）、应变、应变率和心室动脉耦合（有效动脉弹性[Ea]/收缩末期弹性[Ees（sb）]）进行定量。CTRCD定义为EF从基线至基线降低≥ 10%，
OBJECTIVES This study sought to determine the relationships between echocardiography-derived measures of myocardial mechanics and cancer therapeutics-related cardiac dysfunction (CTRCD).BACKGROUND Doxorubicin and trastuzumab are highly effective breast cancer therapies, but have a substantial risk of CTRCD. There is a critical need for the early detection of patients at increased risk of toxicity.METHODS We performed a prospective, longitudinal cohort study of breast cancer participants undergoing doxorubicin and/or trastuzumab therapy. Echocardiography was performed prior to therapy initiation (baseline) and at standardized follow-up intervals during and after completion of therapy. Ejection fraction (EF), strain, strain rate, and ventricular arterial coupling (effective arterial elastance [Ea]/end-systolic elastance [Ees(sb)]) were quantitated. CTRCD was defined as a >= 10% reduction in EF from baseline to